Nephrology Dialysis Transplantation
|
|
- Stephany Patrick
- 6 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (1998) 13 [Suppl 3]: Nephrology Dialysis Transplantation The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure Francisco Llach and Michael Yudd1 Newark Beth Israel Medical Center Nephrology Division, Newark, and 1East Orange VA Center, Nephrology Division, East Orange, NJ, USA important are dietary P intake and the ingestion of phosphate-binding gels. Results from metabolic bal- ance studies indicates that aluminum (Al ) hydroxide gel, ml/day, increases faecal excretion of P by % [5]; however, there is little relationship between the amount of Al hydroxide taken and either the net or relative increase in faecal P. When dietary P intake is <1.09/day and Al hydroxide is taken, faecal P often exceeds dietary intake [6]. However, when dietary P is increased to 2 g/day (64 mmol ), faecal P is usually less than the dietary intake despite ingestion of the gels. Thus, a high P intake can offset an effect of treatment with Al hydroxide or calcium carbonate, emphasizing the need for P restriction together with P binders. Key words: calcitriol; dietary restrictions; hyperphosphataemia; phosphorus binders; secondary hyperparathyroidism Introduction Over the last two decades, significant advances have been made in the pathogenesis of secondary hyperpara- thyroidism (2HPTH) in chronic renal failure (CRF). Thus, calcitriol deficiency and hyperphosphataemia are the most important factors [1,2]. Both calcitriol therapy and appropriate control of hyperphosphatae- mia if instituted early may prevent and/or ameliorate 2HPTH. This in turn results in marked improvement in the bone lesion, osteitis fibrosa, an important clinical expression of 2HPTH. Prevention of hyperphosphataemia is of paramount importance. This has become more relevant after the recent observations that phos- phorus, per se, directly stimulates parathyroid hormone (PTH ) synthesis [3]. Furthermore, hyperphosphatae- mia in dialysis patients has been shown to be a major factor in the worsening of HPTH [4]. We will discuss the clinical importance of hyperphosphataemia both prior to and during calcitriol therapy. Factors affecting serum phosphorus (P) in these patients are summarized in Table 1. Of these, the most Table 1. Factors affecting serum phosphorus in dialysis patients Dietary phosphorus intake Ingestion of phosphorus binders Treatment with vitamin D sterols Frequency, duration and efficiency of dialysis Balance between degradation and synthesis of protein Severity of bone resorption Parenteral alimentation Phosphorus-containing enemas Correspondence and offprint requests to: F. Llach, Newark Beth Israel Medical Center, Nephrology Division, D-4, 201 Lyons Avenue at Osborne Terrace, Newark, NJ 07112, USA. Methods of controlling hyperphosphataemia: Severe hyperphosphataemia usually develops in advanced CRF, most often in patients already on maintenance dialysis. The high serum P not only aggravates the 2HPTH, but it is also an important factor in the development of soft tissue calcifications. The goal of therapy is to reduce serum P to or near normal. In dialysis patients, pre-dialysis serum P should be maintained between 4.5 and 6.0 mg/dl ( mmol/l). Dietary restriction The first important step to control serum P is to decrease the amount of P available for gut absorption. This is achieved by decreasing the intake of protein, especially avoiding protein food stuffs with a high content of P. With commencement of dialytic therapy, it is suggested by the National Cooperative Dialysis Study that patients should ingest a diet containing at least 1 g/kg/day of protein [7]. Metabolic balance studies suggest that a minimum protein intake of 1g/kg/day is necessary to maintain positive nitrogen balance [8]. Thus, Blumenkrantz et al. performed nitrogen balance studies in CAPD patients and noted 1998 European Renal Association European Dialysis and Transplant Association
2 58 F. Llach and M. Yudd near neutral balance when a protein diet of 1 g/kg/day hypercalcaemia most likely due to the use of a high was given, and positive balance was always achieved dialysate Ca concentration ( 3.5 meq/l ). Schaeffer et al. with a dietary protein of 1.2 g/kg/day [8]. have made similar observations [18]. They compared the efficacy of Ca acetate vs Ca carbonate in a 15 week Phosphorus binders cross-over study. Compared with baseline values, both binders significantly reduced serum P and increased Aluminum containing P binders was used for many serum Ca. However, the average amount of elemental years in the control of serum P in patients with CRF. Ca given with Ca acetate was 25.4 mmol as compared As discussed earlier, it was effective and apparently with 46.9 mmol with Ca carbonate (P<0.001). The safe. However, over the last decade, it has become incidence of hypercalcaemia was similar in both groups clear that significant amounts of Al are absorbed by of patients. Similar observations have been made by the gut, resulting in aluminum toxicity [9]. This is other investigators. Thus, it appears that Ca acetate is especially important in certain high risk group of a more efficient binder of P than Ca carbonate, and patients such as diabetic patients [5], prior to parathy- since a lesser amount of elemental Ca needs to be roidectomy [10], aplastic or adynamic bone disease administered, this may lead to lower incidence of [11] and concomitant ingestion of alkalizing agents hypercalcaemia. [12]. Thus, in general, chronic administration of Al Magnesium (Mg) salts are becoming an important binders should be avoided. alternative to the use of Ca-containing P binders. The Calcium salts has been shown to be effective P effect of Mg supplementation on gut phosphorus binders. As the search for a substitute for non-al- absorption has been evaluated by Fine et al. using the containing binders intensified, calcium (Ca) carbonate gastrointestinal waste-out technique [19]. Normal sub- has become the alternative binder. It is inexpensive jects ingested a meal supplemented by 0 38 mmol of and contains a high proportion of elemental Ca (40%). Mg acetate. The fractional gut absorption of P Numerous studies have shown that Ca carbonate is an decreased from 72 to 56% with 5 mmol of Mg acetate, effective P binder. Slatopolsky et al. evaluated the and 28% of the ingested P was absorbed. These experi- effect of this binder in 20 dialysis patients [13]; overall, mental studies were confirmed in clinical studies performed good control of P was achieved during 2 months of by O Donovan et al. [20]. They used Mg treatment. However, because of the ensuing hypercal- carbonate in 28 patients for 2 years, as a substitute for caemia, one-third of the patients still required some Al Al hydroxide. Mg carbonate was administered in doses hydroxide to control serum P. In subsequent studies, of mmol/day for the pre-study period, and these investigators evaluated the long-term effect of Ca dialysate Mg concentration was changed from carbonate together with a lower dialysate Ca concen mmol/l to a free Mg dialysate. With the administration tration in 21 patients [14]. None of those patients of Mg carbonate, a significant reduction in pretration needed supplemental Al hydroxide because hypercalca- dialysis Al was observed, and serum P was under emia was largely avoided with the use of a dialysate control and remained unchanged from previous values. Ca of 2.5 meq/l. Magnesium did not change, remaining between 1.01 Calcium acetate is an effective alternative P binder. and 1.33 mmol/l. Seemingly, Mg carbonate was well Sheik et al., using the gastrointestinal wash-out tolerated by all the patients. Other investigators have method, have evaluated the effect of Ca acetate on Ca also observed the effectiveness of Mg salts as P binders. and P reabsorption as compared with Ca carbonate Thus, Mg carbonate binder together with a free Mg [15]. In normal subjects ingesting a meal containing dialysate is an important alternative to other binders mmol of P, Ca carbonate (25 mmol of elemental Its use not only controls the hyperphosphataemia, but Ca) decreased gut P absorption from 8.5 mmol to also, by decreasing Ca intake, it minimizes the episodes 4.9 mmol/l, whereas Ca acetate decreased it to an of hypercalcaemia. Its use is advisable in dialysis average of 2.9 mmol. The amount of Ca absorbed after patients with HPTH who respond to calcitriol therapy. Ca carbonate was 7.4 mmol as compared with Thus, in these patients, as PTH approaches normal as 5.6 mmol after Ca acetate. Thus the amount of P the result of calcitriol therapy, bone remineralization found per amount of Ca absorbed was practically is almost complete and the tendency to develop hypercalcaemia twice that of Ca acetate. These observations were and hyperphosphataemia is greater since confirmed in studies by Mai et al. in six haemodialysis bone cannot take more minerals. patients [16]; after treatment with Ca carbonate, P absorption decreased by 40% of the ingested load while Ca acetate decreased P absorption by 21.7%. Dialysis of phosphorus Studies by Emmett et al. have evaluated the long- Removal of P by dialysis conceptually should be the term effect of Ca acetate on divalent ion metabolism an appropriate way to control hyperphosphataemia. in 91 dialysis patients [17]. All P binders were discon- Unfortunately, the various dialytic techniques available tinued for 2 weeks before the 3 month study. Ca can not achieve this goal. Recently, Hou et al. have acetate resulted in an increase in serum Ca and a evaluated P removal in dialysis patients treated by decrease in serum P. The dose of elemental Ca necessary dialysis with a blood flow of 300 and a dialysate flow for P control was mmol per meal of 500 ml/min [21]. The pre-dialysis P averaged ( mg per meal ), and 17 patients developed 6.8 mg/dl (2.2 mmol/l ). They observed a high rate of
3 Importance of hyperphosphataemia in hyperparathyroidism 59 P removal in each stage of dialysis, which steadily increased concentrations during the inter-dialytic interval declined during the 4 h of dialysis. The decline was in these patients. Presumably this arises because due to an efflux of P from the intracellular space and bone resorption is markedly increased with efflux of P bone to the extracellular space as the result of the from bone to blood. In these patients, a marked early decrease in serum P. Overall, 1 g of P was reduction in serum P often follows parathyroidectomy removed with each dialysis. Removal of P by dialysis or when parathyroid hormone (PTH) is decreased by was not affected by the type of dialyser membrane, the i.v. calcitriol. Another problem with the hyperphosphataemia dialytic technique or the dialysate Ca concentration. of these patients may be the development, Thus, Shinaberger et al. observed a net P removal of at the parathyroid gland level, of non-responsiveness mg during 4 h of conventional haemodialysis to the PTH-inhibitory action of calcitriol. Thus, which increased only to mg during 3 h of high recently, we have observed worsening of 2HPTH in efficiency or high flux haemodialysis [22]; no significant two patients receiving an appropriate dose of intraven- changes were observed using acetate, polysulphone, ous calcitriol [25]. In these two patients, although and other highly permeable membranes. Interestingly, there was an initial response to i.v. calcitriol character- correction of the anaemia with erythropoietin decreases ized by a marked decrease in PTH, as severe hyperphosphataemia P removal by 18%. Recently, it has been suggested developed, a gradual and steady that bicarbonate rather than acetate may increase the increment of PTH was observed ( Figure 1). This intracellular pool of P and thus decrease the serum P occurred despite the presence of mild hypercalcaemia concentration. However, preliminary studies compar- and appropriate blood levels of calcitriol. ing dialysate containing the two buffers showed no Appropriate knowledge of the dietary habit of the significant differences in the transference of P [23]. In patient is of utmost importance. Thus, the number of CAPD patients, the clearance of P is ~4.7 ml/min meals per day and the amount of P ingested with each with each dialysate exchange; 65 mg (2.1 mmol ) is meal should be evaluated so that the dose of the P recovered, resulting in a daily removal of P of 307 mg binder prescribed is commensurate with the size of the (9.9 mmol ). Thus, CAPD in general is not better than meal. Schiller et al., using the gastrointestinal washout haemodialysis in removing P. technique in normal subjects, observed that the However, in the presence of appropriate dietary dose and time of administration of the P binder had a intake and adequate nutrition, the presence of hyperphosphataemia significant effect on the amount of P absorbed by the may be a reflection of inadequate dia- gut [26]. Thus, when 25 mmol of Ca acetate was given lysis. In these situations, it is important to ensure that during a standard meal, the percentage of P absorbed adequate dialysis is administered by checking and being decreased from a baseline of 78 to 31%. On the other certain that the Kt/V is >1.2. Over the last few years, hand, when Ca acetate was given in the fasting state the USRD data have shown that the presence of or 2 h post-prandially, the percentage of P absorbed hyperphosphataemia is associated with increased morbidity by the gut increased to 42%. Likewise, Ca absorption and mortality in the US dialysis population. after Ca acetate ingested during the meal was 21% and This is more clear once serum P increases >6.5 mg/dl. it increased to 40% when given in the fasting state. These observations clearly suggest that the larger dose Failure to control hyperphosphataemia of the P binder should be given during the largest meal of the day. The most common cause is poor compliance, both Likewise, intestinal absorption of P also increases with diet and P binders. Often this problem is related after calcitriol therapy [28]; thus, hyperphosphataemia to a lack of both educational dietary training and is not uncommon after oral calcitriol [1,5]. The magni- support from the dietician and nursing staff. A close tude of this increment seems to be less with i.v. than interaction with a social worker is also essential, since with oral calcitriol. food containing low biological value protein with a high content of P may be all the patient can afford. It is clear that this is a difficult problem with no easy Hyperphosphataemia during calcitriol therapy solution. However, a supporting nursing staff with frequent counselling by the dietician and appropriate As can be seen in Figure 2, hyperphosphataemia may follow-up by the social worker is usually most not only lead to soft tissue calcification, and worsening beneficial. of HPTH, but it may also alter the response to calcitriol The variability in dissolution rate among the different therapy. Thus, another emerging cause of failure to brands of Ca salts was noted by Kobrin et al. [24]. control 2HPTH despite appropriate calcitriol therapy He noted in two patients, using abdominal X-rays, the is the presence of significant hyperphosphataemia. Of presence of undisintegrated tablets in the bowel. particular interest is the observation in our previous Furthermore, intact tablets were found in the faeces study [25] of two patients, in whom we observed a of one patient. In general, generic brands seem to be decreased basal and maximal PTH after 10 weeks of the worst offenders. calcitriol treatment. These patients later developed Severe secondary hyperparathyroidism usually is reflected in a more severe hyperphosphataemia; there may also be a more rapid rebound of serum P to severe hyperphosphataemia and simultaneously the serum PTH increased, despite continued calcitriol therapy. These findings suggest that P per se may lead
4 60 F. Llach and M. Yudd Fig. 1. The effect of severe hyperphosphaetamia (left) on PTH (on the right) in a patient with significant hyperparathyroidism receiving calcitriol, 2 mg i.v., three times a week at the end of each dialysis. Note the initial decrease in PTH and phosphorus with initiation of calcitriol therapy. However, as the patient developed hyperphosphataemia because of a well-documented poor dietary compliance, there is a progressive increase in PTH to levels above baseline (reference 25). to worsening of 2HPTH and resistance to the inhibitory effect of calcitriol on PTH synthesis. Fernandez and Montoliu evaluated parathyroid function and hyperphosphataemia in dialysis patients. The presence of hyperphosphataemia displaced the PTH Ca curve References toward the right in only 3 days [27]. We have recently Fig. 2. Diagram describing the various ill effects of hyperphosphaeta- mia in patients with CRF. roidectomy was carried out in two of these patients. Thus, persistent hyperphosphataemia, not amenable to strict dietary counselling, may lead to resistance to calcitriol and surgical intervention. In summary, control of hyperphosphataemia is of the utmost importance in patients with advanced CRF. Hyperphosphataemia, if not controlled, leads to severe 2HPTH and soft tissue calcifications. Restriction of dietary P together with an appropriate protein intake is an essential first therapeutic step. Calcium salts are the P binders of choice at the present time; however, Mg carbonate is an excellent alternative. The dose of the P binder should be individualized and prescribed in a manner commensurate with the P content of each meal. Al-containing P binders should be avoided whenever possible. Finally, during calcitriol therapy, hyperphosphataemia may develop and, unless it is controlled, worsening of HPTH and resistance to calcitriol therapy may develop. Acknowledgements. The authors thank Leda Reeves for providing secretarial assistance in the preparation of this manuscript. evaluated the problem of hyperphosphataemia in Llach F, Coburn JW. Renal osteodystrophy and maintenance dialysis. In: Maher JF, ed. Replacement of Renal Function by patients with severe HPTH (PTH>1200 pg/ml ) receiv- Dialysis, Dordrecht/Boston/Lancaster: Klewer Academic ing i.v. calcitriol therapy for 18 months [28]. Calcitriol Publishers, 1989: therapy was started once serum P was <6.5 mg/dl; the 2. Slatopolsky E, Bricker NA. The role of phosphorus restriction mean initial dose was 4 mg i.v. after each dialysis. The in the prevention of secondary hyperparathyroidism in chronic mean PTH prior to therapy was 1650 pg/ml and, after renal disease. Kidney Int 1973; 4: Hernandez A, Concepcion MT, Rodriguez M, Salido E, 18 months of therapy, it had decreased to 225 pg/ml. Torres A. High phosphorus diet increases prepro PTHm RNA However, in three of these patients, isolated episodes independent of calcium and calcitriol in normal rats. Kidney Int of hyperphosphataemia were noted and this was 1996; 50: accompanied by a delta increase in PTH of 950 pg/ml. 4. Walling MW. Intestinal Ca and phosphate transport: differential This increase in PTH occurred despite appropriate i.v. responses of vitamin D metabolites. Am J Physiol 1977; 133: Llach F, Nikathar B. Current advances in the therapy of dosing of calcitriol. As the hyperphosphataemia was secondary hyperparathyroidism and osteitis fibrosa. Miner controlled with dietary counselling, the PTH decreased Electrolyte Metab 1991; 17: and, by the end of the 18 months, PTH was 6. Clarkson EM, Luck VA, Hynson WV. The effect of aluminum <200 pg/ml. However, in three other patients, hydroxide on calcium, phosphorus and aluminum balances, the serum parathyroid hormone concentration and the aluminum repeated episodes of persistent hyperphosphataemia content of bone in patients with chronic renal failure. Clin Sci developed. This precluded the appropriate use of 1972; 43: 519 vitamin D. By the end of the follow-up period, parathy- 7. Gotch FA, Sargent JA. A mechanistic analysis of the National
5 Importance of hyperphosphataemia in hyperparathyroidism 61 Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28: 18. Schaefer K, Scheer J, Asmus G et al. The treatment of uremic hyperphosphatemia with calcium acetate and calcium carbonate. 8. Blumenkrantz MJ, Kopple JD, Moran J, Coburn JW. Metabolic Nephrol Dial Transplant 1991; 6: balance studies and dietary protein requirements in patients 19. Fine KD, Santa Ana CA, Porte JL et al. Intestinal absorption undergoing continuous peritoneal dialysis. Kidney Int 1982; of magnesium from food and supplements. J Clin Invest 1991; 21: : Llach F, Felsenfeld AJ, Coleman M, Keveney J Jr, Pederson 20. O Donovan R, Baldwin D, Hammer D, Moniz C. Substitution JA, Medlock T. The natural course of dialysis osteomalacia. of aluminum salts by magnesium salts in control of dialysis Kidney Int 1986; 29: S74 S79 hyperphosphatemia. Lancet 1986; i: Felsenfeld AJ, Harrelson JM, Gutman RA. Osteomalacia after 21. Hou SH, Zhao J, Ellman CF et al. Calcium and phosphorus parathyroidectomy in patients with uremia. Ann Intern Med fluxes during hemodialysis with a low calcium dialysate. Am 1984; 96: 34 J Kidney Dis 1991; 18: Felsenfeld AJ, Rodriguez M, Dunlay R, Llach F. A comparison 22. Shinaberger JH et al. Studies of phosphate removal in clinical of parathyroid gland function in hemodialysis patients with dialysis (abstract). Kidney Int 1984; 25: 193 different forms of renal osteodystrophy. Nephrol Dial Transplant 23. Miller JH, Gardner PW, Heinekin F, Samar R, Shinaberger JH. 1991; 6: Studies of inorganic phosphate removal during acetate and 12. Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity bicarbonate dialysis. Proc Am Soc Artif Int Org 1983; 12: 57 associated with oral citrate and aluminum containing antacids. 24. Kobrin SM, Goldstein SJ, Shangraw RF et al. Variable efficacy Am J Med Sci 1989; 297: 9 of calcium carbonate tablets. Am J Kidney Dis 1989; 14: Slatopolsky E, Weerts C, Lopez-Hilker S. Calcium carbonate as 25. Rodriguez M, Felsenfeld AJ, Dunlay R, Williams C, Pederson a phosphate binder in patients with chronic renal failure under- JA, Llach F. The effect of long term intravenous calcitriol going dialysis. N Engl J Med 1986; 315: 157 administration on parathyroid function in hemodialysis patients. 14. Slatopolsky E, Weerts C, Norwood K et al. Long term effects J Am Soc Nephrol 1991; 2: of calcium carbonate and 2.5 Meq/liter calcium dialysate on 26. Schiller L, Santa Ana CA, Sheikh M, Emmett M, mineral metabolism. Kidney Int 1989; 36: Fordtram J. Effect of the time of administration of calcium 15. Sheikh M, Maguire J, Emmett M et al. Reduction of dietary acetate on phosphorus binding. N Engl J Med 1989; 320: phosphorus absorption by phosphorus binders. J Clin Invest ; 83: Fernandez E, Montoliu J. Successful treatment of massive uremic 16. Mai M, Emmett M, Sheikh M, Santa Ana CA, Schiller L, tumoral calcinosis with daily hemodialysis and very low calcium Fordtran J. Calcium acetate, an effective phosphorus binder in dialysate. Nephrol Dial Transplant 1994; 9: patients with renal failure. Kidney Int 1989; 36: Llach F, Hervas J, Yudd M, Goldblat, MV. Hyperphosphatemia 17. Emmett M, Sirmon MD, Kirkpatrick WA et al. Calcium acetate worsened parathyroid function in dialysis patients with severe control of serum phosphorus in hemodialysis patients. Am hyperthyroidism received intravenous calcitriol. J Am Soc J Kidney Dis 1991; 27: Nephrol 1996; 7: 1794
Secondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant ( 1997) 12: 1223 1228 Original Article Nephrology Dialysis Transplantation Reduced calcium dialysate in CAPD patients: ecacy and limitations A. Armstrong1, J. Beer1, K. Noonan2
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationClinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationOriginal epidemiologic studies 1 have suggested that approximately
Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of
More informationGuidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism
Nephrol Dial Transplant (16) 11 [Suppl 3]: 6-101 Nephrology Dialysis Transplantation Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism E. Fernandez 1 and F.
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationMalnutrition and Role of Nutrition in BMD:CKD
Malnutrition and Role of Nutrition in BMD:CKD PNDS Continuing Nutrition Education Seminar Saturday, 30 th November 2013 Fayza Khan MSC (Foods and Nutrition) R.D President,PNDS Outline Objective Malnutrition
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationControl of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis
Kidney International, Vol. 53 (1998), pp. 1399 1404 Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis ISTVAN MUCSI, GAVRIL HERCZ, ROBERT ULDALL, MICHAELENE
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationDraft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)
Draft Labeling Package Insert Not Actual Size BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate) DESCRIPTION: Full Size: Each opaque capsule with a white cap and white body is spin printed
More informationDifferent effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism
Nephrol Dial Transplant (996) : 8-87 Original Article Nephrology Dialysis Transplantation Different effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationLevel 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor
chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for
More informationThe Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels
17.6 The Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels Partially embedded in the posterior surface of the lateral lobes of the thyroid gland
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 01 June 2007 Product Name : Renagel Procedure No: EMEA/H/C/000254/II/56 SCIENTIFIC DISCUSSION 1/11 1. Introduction Renagel (sevelamer), a non-absorbed, calcium and metal-free
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationCOMMON MEDICINES USED IN CKD CHRONIC KIDNEY DISEASE
CHRONIC KIDNEY DISEASE 1 This information is intended to help you understand why you need to take your medicines. There are multiple medicines that are used to control the symptoms related to CKD. You
More informationBONE AND MINERAL METABOLISM in the PD PATIENT
BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationLanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding
Renal Failure, 34(3): 263 270, (2012) Copyright Informa Healthcare USA, Inc. ISSN 0886-022X print/1525-6049 online DOI: 10.3109/0886022X.2011.649657 Lanthanum Carbonate Reduces Urine Phosphorus Excretion:
More informationA new era in phosphate binder therapy: What are the options?
http://www.kidney-international.org & 2006 International Society of Nephrology A new era in phosphate binder therapy: What are the options? IB Salusky 1 1 Department of Pediatrics, David Geffen School
More informationA Comparison of Calcium-Based Phosphorus Binders for Patients with Chronic Kidney Disease
A Comparison of Calcium-Based Phosphorus Binders for Patients with Chronic Kidney Disease Michael Emmett, MD The author is with the Department of Internal Medicine, Baylor University Medical Center, Dallas,
More informationNDT Advance Access published February 3, 2007
NDT Advance Access published February 3, 2007 Nephrol Dial Transplant (2007) 1 of 6 doi:10.1093/ndt/gfl840 Original Article Implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and
More informationDietary phosphate restriction in dialysis patients: A new approach for the treatment of hyperphosphataemia
Nutrition, Metabolism & Cardiovascular Diseases (2010) xx, 1e6 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/nmcd Dietary phosphate restriction in dialysis patients: A new
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationNew Phosphate Binding Agents: Ferric Compounds
New Phosphate Binding Agents: Ferric Compounds J Am Soc Nephrol 10: 1274 1280, 1999 CHEN H. HSU, SANJEEVKUMAR R. PATEL, and ERIC W. YOUNG Nephrology Division, Department of Internal Medicine, University
More informationRacial differences in bone turnover rate and hyperparathyroidism in hemodialysis patients
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 1994 Racial differences in bone turnover rate and hyperparathyroidism
More informationChronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
This is an official Northern Trust policy and should not be edited in any way Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Reference Number: NHSCT/12/553 Target
More informationMajor intra and extracellular ions Lec: 1
Major intra and extracellular ions Lec: 1 The body fluids are solutions of inorganic and organic solutes. The concentration balance of the various components is maintained in order for the cell and tissue
More informationParsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1
Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Not an actual Parsabiv vial. The displayed vial is for illustrative
More informationRenal Osteodystrophy in Pediatric Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 20, 2004 Francisco J. Cano, Marcela Valenzuela, Pedro Zambrano, Marta A. Azocar, Eduardo Wolff, Maria A. Delucchi, Eugenio E. Rodriguez Renal Osteodystrophy in Pediatric
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More informationMetabolic Bone Disease (Past, Present and Future Challenges in the Management)
Metabolic Bone Disease 871 151 Metabolic Bone Disease (Past, Present and Future Challenges in the Management) SNA RIZVI INTRODUCTION The past 40 years have seen some important historical events leading
More informationBsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients
Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco
More informationThe hart and bone in concert
The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel
More informationAbnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism
Nephrol Dial Transplant (1996) 11: 1292-1298 Original Article Mephrology Dialysis Transplantation Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud, A.
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson- Zachrisson,
More informationAna Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto
Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate
More informationThe Effect of Long-Term Intravenous Calcitriol Administration on Parathyroid Function in Hemodialysis
The Effect of Long-Term Intravenous Calcitriol Administration on Parathyroid Function in Hemodialysis 12 Mariano Rodriguez,3 Arnold J. Felsenfeld, Carl Williams, James A. Pederson, and Francisco Liach
More informationControl of hyperphosphatemia is a major goal in patients
ORIGINAL ARTICLES Phosphorus Clearance Using Two Hemodialyzers Placed in Parallel Mitchell H. Rosner, 1,2 Allen Helmandollar, 1 Ryan Evans, 1 Emaad Abdel-Rahman 1 Division of Nephrology, 1 University of
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationGuidelines for the Management of Nutrition
S 42 Indian Journal of Nephrology Introduction Protein-energy malnutrition (PEM) is very common among patients with advanced chronic kidney disease (CKD). In the Indian scenario, where malnutrition is
More informationNew Medicines Profile. December 2013 Issue No. 13/04. Colestilan
New Medicines Profile December 2013 Issue. 13/04 Concise evaluated information to support the managed entry of new medicines in the NHS Summary (BindRen ) is an oral, non-absorbed, non-calcium, nonmetallic
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationPRIMARY HYPERPARATHYROIDISM
PRIMARY HYPERPARATHYROIDISM HYPERPARATHYROIDISM Inappropriate excess secretion of Parathyroid Hormone in Primary Hyperparathyroidism Appropriate Hypersecretion in Secondary Hyperparathyroidism PTH and
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationUse of magnesium as a drug in chronic kidney disease
Clin Kidney J (2012) 5[Suppl 1]: i62 i70 doi: 10.1093/ndtplus/sfr168 Use of magnesium as a drug in chronic kidney disease Alastair J. Hutchison 1 and Martin Wilkie 2 1 University of Manchester and Manchester
More informationVelphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationThis review examines the dynamics of parathyroid hormone
In-Depth Review Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Arnold J. Felsenfeld,* Mariano Rodríguez, and Escolástico Aguilera-Tejero *Department of Medicine,
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationInvestigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis
Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis Tutorial for Specialist Portfolio Biomedical Scientists 03/02/2014 Dr Petros Kampanis Clinical Scientist 1. Calcium Most abundant
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationUPDATE ON RENAL OSTEODYSTROPHY: PATHOGENESIS AND CLINICAL MANAGEMENT
UPDATE ON RENAL OSTEODYSTROPHY: PATHOGENESIS AND CLINICAL MANAGEMENT KhashayarSakhaee,M.D. University of Texas Southwestern Medical Center at Dallas Internal Medicine Grand Rounds May 22, 1997 Name: Rank:
More informationCross-linked iron dextran is an efficient oral phosphate binder in the rat
Nephrol Dial Transplant (1996) 11: 808-81 Original Article Nephrology Dialysis Transplantation Cross-linked iron dextran is an efficient oral phosphate binder in the rat K. Spengler 1, H. Follmann 1, K.-S.
More informationNocturnal but not Short Hours Quotidian Hemodialysis Requires an Elevated Dialysate Calcium Concentration
J Am Soc Nephrol 14: 2322 2328, 2003 Nocturnal but not Short Hours Quotidian Hemodialysis Requires an Elevated Dialysate Calcium Concentration FAYEZ AL-HEJAILI, CLAUDE KORTAS, ROSEMARY LEITCH, A. PAUL
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2006) 21: 1663 1668 doi:10.1093/ndt/gfl006 Advance Access publication 6 February 2006 Original Article Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism
More informationAmol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through
Research Article ISSN: 0974-6943 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through www.jpronline.info Comparison of efficacy and safety of Cinacalcet versus Calcitriol
More informationLLL Session - Nutritional support in renal disease
ESPEN Congress Leipzig 2013 LLL Session - Nutritional support in renal disease Peritoneal dialysis D. Teta (CH) Nutrition Support in Patients undergoing Peritoneal Dialysis (PD) Congress ESPEN, Leipzig
More informationBEC FEED SOLUTIONS NEW ZEALAND Ltd
BEC FEED SOLUTIONS NEW ZEALAND Ltd Proudly sponsor Dr Alessandro Mereu Yara Feed Phosphates July 2017 NZARN Meeting www.becfeed.co.nz Phosphorus metabolism in cattle: principles and interactions with Ca
More informationELECTROLYTES RENAL SHO TEACHING
ELECTROLYTES RENAL SHO TEACHING Metabolic Alkalosis 2 factors are responsible for generation and maintenance of metabolic alkalosis this includes a process that raises serum bicarbonate and a process that
More information1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown
Medical-Surgical Nursing Care Second Edition Karen Burke Priscilla LeMone Elaine Mohn-Brown Chapter 7 Caring for Clients with Altered Fluid, Electrolyte, or Acid-Base Balance Water Primary component of
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationDirect inhibitory effect of calcitriol on parathyroid function
Kidney International, Vol. 36 (1989), pp. 1093 1098 Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis ROBERT DUNLAY, MARIANO RODRIGUEZ, ARNOLD J. FELSENFELD,
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationNOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT Phosphate Binders for the Treatment of Hyperphosphataemia in adults with Chronic Kidney Disease OBJECTIVES To outline referral
More informationChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist
More informationThe Management of Phosphataemia in Renal Dogs or Cats
The Management of Phosphataemia in Renal Dogs or Cats improves both the quality of life and the life expectancy of animals. THE CARDIOLOGY - NEPHROLOGY DIMENSION PAIN INFLAMMATION ANTI-INFECTIVE PHOSPHATAEMIA
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationEffect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
Research Article Effect of lanthanum and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease P. Thomas Scaria, Reneega Gangadhar 1, Ramdas Pisharody 2 ABSTRACT Departments
More informationEffectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients
Open Access Journal of Journal of Parathyroid Disease 2017,5(1),17 24 http://www.jparathyroid.com Original Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis
More informationTenapanor, a minimally absorbed NHE3 inhibitor, reduces dietary phosphorus absorption in healthy volunteers
, a minimally absorbed NHE3 inhibitor, reduces dietary phosphorus absorption in healthy volunteers David Rosenbaum, 1 Susanne Johansson, 2 Björn Carlsson, 2 Andrew G Spencer, 1 Bergur Stefansson, 2 Mikael
More informationThe goal of dialysis for patients with chronic renal failure is to
Dialysate Composition in Hemodialysis and Peritoneal Dialysis Biff F. Palmer The goal of dialysis for patients with chronic renal failure is to restore the composition of the body s fluid environment toward
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationTHE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE
THE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE THE DIALYSIS CYCLE /TIME DESIGN OF THE NATIONAL COOPERATIVE DIALYSIS STUDY
More information